Your Article Summary
See Latest ArticlesCorcept Therapeutics Announces Negative Results From the First of Three Phase 3 Studies Evaluating CORLUX(R) for Treating the Psychotic Features of Psychotic Major Depression
Corporate News Releases - The Healthcare Sales & Marketing Network, 08/28/06
Corcept Therapeutics, Incorporated announced that the first of its three Phase 3 trials evaluating CORLUX for treating the psychotic features of Psychotic Major Depression (PMD) was negative. Study 07 was a randomized, double-blind, placebo-controlled study
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/11/09
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09